Elastin Breakdown Products May Drive Insulin Resistance as You Age

Elastin-derived peptides (EDPs) — fragments released when the structural protein elastin breaks down during aging — were found to directly cause insulin resistance in mice. When injected intravenously (either as a single dose or repeatedly), EDPs triggered hyperglycemia and reduced glucose uptake in skeletal muscle, liver, and adipose tissue. The mechanism involves EDPs activating the elastin receptor complex, whose neuraminidase-1 subunit then interacts with the insulin receptor. This interaction strips sialic acid residues from the insulin receptor's beta-chain, impairing its signaling cascade. This is the first study to show that elastin degradation products — which naturally accumulate as we age — can directly interfere with insulin signaling and promote insulin resistance.

The researchers used a combination of in vivo mouse experiments, in vitro cell studies, and computer modeling. C57BL/6 mice on a standard diet received either acute or chronic intravenous injections of elastin-derived peptides. Blood glucose levels and tissue-specific glucose uptake were measured. The molecular mechanism was investigated by examining the interaction between the elastin receptor complex (specifically its neuraminidase-1 subunit) and the insulin receptor, including analysis of sialic acid levels on the insulin receptor's beta-chain.

This study offers a novel explanation for why insulin resistance tends to develop with aging. Rather than focusing on the usual suspects like diet, obesity, or inflammation, it points to a structural change: the gradual breakdown of elastin in blood vessel walls and connective tissue releases peptide fragments that actively disrupt insulin signaling. If confirmed in humans, this could open entirely new therapeutic targets for age-related type 2 diabetes.

Most insulin resistance research focuses on obesity, diet, and inflammation. This study introduces a completely different mechanism — the degradation of structural proteins during aging. It connects the fields of vascular biology and metabolic disease, suggesting that the extracellular matrix is not just passive scaffolding but an active regulator of metabolism. If elastin-derived peptides contribute to insulin resistance in humans, therapies that prevent elastin degradation or block the elastin receptor could become new strategies for preventing age-related diabetes.

This was an animal study using C57BL/6 mice, so the findings may not directly translate to humans. The EDPs were delivered intravenously rather than accumulating naturally, which may not perfectly replicate the aging process. The study did not measure the actual concentrations of EDPs that accumulate in aging tissues in vivo, making it difficult to know whether physiologically relevant levels would produce the same effects.